Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03430791 · ClinicalTrials.gov registry record · Phase 2
Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma
A Phase 2 study, sponsored by Baptist Health South Florida.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT03430791 is a Phase 2 study that was terminated before completion, run by Baptist Health South Florida. The registered enrollment target is 5 participants.
The verdict
NCT03430791, a Phase 2 study, was terminated before completion, sponsored by Baptist Health South Florida.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.
Interventions
- DRUG Nivolumab 240 mg IV
- DRUG Nivolumab 3 mg/kg
- DRUG Ipilimumab 1 mg/kg
- DEVICE NovoTTF200A (Optune)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-12-05 |
| Est. Completion | 2021-01-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03430791
The ClinicalTrials.gov registry entry for NCT03430791 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Nivolumab 240 mg IV is the first listed.
NCT03430791 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03430791 about?
NCT03430791 is a clinical study titled "Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent Glioblastoma". Phase I/II trial in which participants with recurrent glioblastoma will receive a combination of tumor treating fields(portable device), nivolumab with or without ipilimumab.
What is the current status of trial NCT03430791?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2018-12-05. Estimated completion is 2021-01-27.
What interventions are being tested in trial NCT03430791?
The interventions under investigation include: Nivolumab 240 mg IV (DRUG), Nivolumab 3 mg/kg (DRUG), Ipilimumab 1 mg/kg (DRUG), NovoTTF200A (Optune) (DEVICE).
Who is sponsoring clinical trial NCT03430791?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.